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Abstract
Background: Globally, the number of people who die with dementia is increasing. The importance of a palliative
approach in the care of people with dementia is recognised and there are national polices to enhance current care.
In the UK implementation of these polices is promoted by the National Institute for Health and Care Excellence
(NICE) Dementia Quality Standards (QS). Since publication of the QS new care interventions have been developed.
Aim: To explore critically the current international research evidence on effect available to inform NICE Dementia
QS relevant to end of life (EOL) care.
Design: We used systematic review methods to seek the research evidence for three statements within the
Dementia QS. These are those that recommend: (1) a case management approach, (2) discussing and consideration
of making a statement about future care (SFC) and (3) a palliative care assessment (PCA). We included evaluative
studies of relevant interventions that used a comparative design, such as trials and cohort studies, and measured
EOL care outcomes for persons dying with moderate to severe dementia. Our primary outcome of interest was
whether the intervention led to a measurable impact on wellbeing for the person with dementia and their family.
We assessed included studies for quality using a scale by Higginson and colleagues (2002) for assessment of quality
of studies in palliative care, and two authors undertook key review processes. Data sources included Cinahl,
Embase, and PsychINFO from 2001 to August 2014. Our search strategy included free text and medical subject
headings relevant to population and recommended care.
Results: We found seven studies evaluating a care intervention; four assessed SFC, three PCA. None assessed case
management. Studies were of weak design; all used retrospective data and relied on others for precise record
keeping and for accurate recall of events. There was limited overlap in outcome measurements. Overall reported
benefits were mixed.
Conclusions: Quality statements relevant to EOL care are useful to advance practice however they have a limited
evidence base. High quality empirical work is needed to establish that the recommendations in these statements
are best practice.
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Background
Dementia is a progressive neurodegenerative disease for
which there is currently no disease modifying treatment.
Across the world a large and increasing number of
people are living with dementia. In the UK approxi-
mately 835,000 people have dementia [1] and estimates
suggest that of those aged 65 years and over, one in
three will die either with or from the disease [2]. The
need for appropriate care and support for people with
dementia is a recognised priority [3].
The importance of a palliative approach in the care
of people with dementia is recognised at international
level [4, 5], and there are national initiatives that aim
to guide clinicians, and policy-makers to provide the
most appropriate care at the end of life (EOL) [6].
The UK Department of Health’s End of Life Care
Strategy is an example [7]. It is a general strategy ir-
respective of disease since many principles of care are
common for all who are approaching death. However,
compared with cancer or other chronic diseases,
people with dementia may have different EOL needs, in-
cluding communication and cognitive difficulties [8, 9].
There are policy initiatives specific to dementia including,
in the UK, Living Well with Dementia: a national
dementia strategy [10], these though do not provide prin-
ciples for EOL care.
Care quality indicators are used (for example in the
UK, the Netherlands, Australia) to help drive improve-
ment in areas of high priority [11]. They are measurable
aspects of care for which quality standards (QS) are de-
veloped [12]. In the UK, they are developed by the
National Institute for Health and Care Excellence
(NICE) and there are two QS specific to dementia:
QS13, published in 2014 is on living well with dementia
[13]; and QS1, published in 2010 is on health and social
care which has three statements relevant to EOL care
[14]. There is no agreed definition of QS, in general
they are based on clinical guidelines and/or published
evidence and are composed of concise statements that
aim to set guidance on what is minimally acceptable
as good practice. In the recent political climate they
have assumed a significant profile as central, although
not mandatory, in their application to delivery of the
NHS. (12) A recent systematic review of the inter-
national literature on clinical guidelines in dementia
highlighted the limited number of recommendations
provided in guidelines on EOL care [15].
However, since the millennium, there have been in-
terventions introduced that are relevant to EOL for
people with dementia, including advance care plan-
ning (ACP), a palliative approach to care and case
management. Advance care planning (ACP) involves
discussion of future care preferences to develop an
understanding of an individual‘s wishes should they
become unable to make decisions for themselves. This
may lead to the individual making a statement about
future care (SFC) [16]. This has particular resonance
in dementia where people may become unable to par-
ticipate in decisions about their care in the later
stages of dementia or at the EOL. The benefits of this
intervention though are not fully established and eval-
uations on ACP continue to be undertaken [17].
There is also international work that aims to clarify
both the nature of a palliative approach to care for
people with dementia and how it might be imple-
mented [5]. For example, the Palliative Excellence in
Alzheimer Care Efforts (PEACE) programme is a dis-
ease management program that incorporates a pallia-
tive care focus from the diagnosis of dementia
through its terminal stages [18]. Case management in-
volves a pro-active approach to care, identifying the
needs of people with complex conditions and devel-
oping a personalised care plan [19]. It often involves
establishing a key worker to co-ordinate care and this
approach is relevant at all stages of dementia. We are
aware of evaluations of such interventions in demen-
tia, although they may not all involve care at the
EOL [20–25].
Given that the UK Department of Health depends upon
QS to drive improvements in care, it is important that
such initiatives are informed by research evidence [26]. A
review of this evidence is valuable to inform future think-
ing on both recommendations for care and priorities for
new research.
Aim
In this paper, we explore critically the current inter-
national research evidence on effect available to inform
the following NICE Dementia QS1 statements relevant
to EOL care:
 Statement 4 (S4): People with dementia have an
assessment and an ongoing personalised care plan
agreed across health and social care that identifies a
named care coordinator and addresses their
individual needs.
 Statement 5 (S5): People with dementia, while they
have capacity, have the opportunity to discuss and
make decisions, together with their carer/s, about
the use of advance statements, advance decisions to
refuse treatment, lasting power of attorney and
preferred priorities of care.
 Statement 9 (S9): People in the later stages of
dementia are assessed by primary care teams to
identify and plan their palliative care needs.
Our primary outcomes of interest were wellbeing of
the person with dementia and of their family.
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Method
We used systematic review methods guided by the
Cochrane Handbook [27] and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
guidelines [28].
Inclusion criteria
We sought first to identify randomised controlled trials
(RCTs) however we were aware that the number of such
studies might be limited. This is in part due to the
ethical issues involved in withholding treatments or
care from people with dementia and/or those nearing
the EOL. Involvement in research may be perceived
as burdensome and upsetting for patients and their
families [29]. We therefore also included more prag-
matic evaluative studies that used any comparative
design such as quasi-controlled trials, observational
and cohort studies with a comparative arm and
before-and-after studies.
We included studies of populations with dementia or
documented cognitive deficit. We did not require spe-
cific diagnostic inclusion criteria for dementia, as many
people never receive a formal diagnosis [30]. We set two
criteria of increased relevance for EOL: (1) participants
at the EOL were described as having moderate, severe or
advanced dementia, (2) study assessed outcomes re-
lated to EOL care, such as pain control, place of
death or type of care (e.g. use of palliation or life-
sustaining treatments). For S5 we set an additional
criterion that the studies involved the process of con-
sidering preparing SFC at a period when the person
with dementia still had capacity.
The criteria for the interventions selected were that
they should combine all of the core requirements of
each individual statement, which the research team
interpreted as:
 S4: (1) a named care coordinator, (2) an assessment
of health and social care needs, (3) a personalised
care plan, and (4) integration/co-ordination of
care services.
 S5: (1) people with early dementia who retained
mental capacity and had made decisions regarding
future healthcare preferences including the use of
advance statements and/or advance decisions to
refuse treatment and/or lasting power of attorney
and/or preferred priorities of care.
 S9: (1) an assessment of palliative care needs, (2) a
palliative care plan, and (3) delivery within a primary
care or community setting.
The setting of the delivery of the intervention could be
the participant’s home, a care or nursing home (NH) or
other community facility.
Exclusion criteria
We excluded studies if they were concerned only with
acute care delivered within secondary care settings. We
did not include studies of people at the EOL with mild
dementia. If the severity of dementia was mixed, we ex-
cluded the study unless more than 33 % of the sample
had moderate or severe dementia and where possible we
reported these results only.
Information sources
We searched five citation databases, CINAHL, Embase,
PsychINFO, Cochrane and Web of Science, from
January 2001 to August 2014. We chose this start date
because from 2001 there has been increased recognition
by governments and other public agencies, and therefore
a likely increase in research in dementia.
Search strategy
The search strategy was developed through consultation
within our specialist dementia research group and re-
fined using test searches with medical subject headings
(MESH) and text terms. The search terms for each state-
ment are shown in Table 1. Abstracts of citations identi-
fied were screened; S4 and S9 by ME, S5 by ME and
KM. A subsample of each search was independently
checked by BC to ensure consistency when applying in-
clusion criteria. Full text of citations which appeared
relevant were checked for eligibility by ME and BC.
Reference lists were checked for further relevant studies.
Assessment of quality and risk of bias
We assessed the quality of studies using an approach de-
veloped by Higginson et al. [31] that is relevant for re-
views in palliative care. The approach grades by study
Table 1 Search terms for three NICE Quality Care Statements
Search terms for dementia: Dementia or Alzheimera or lewy body or
lewy bodies or cognitive impaira or capacity impaira or lacka capacity
or memory loss
Search terms used for standard S4:
Key worker or key carer or named worker or named care co-ordinator
or named carer or community psychiatric nurse or liaison worker or
link worker or community health nursing.
Search terms used for standard S5:
(Advancea (plan or care or directive or decision or contract or
statement)) or living willa or right to die or power of attorney or
ulysses (contracta or directivea) or PPC or preferred priorities of
care or anticipatory care plan.
Search terms used for standard S9:
(Primary care or general practice or community care or care in the
community or family physician or community nurse or practice nurse)
AND (Palliative care or end-of-life or symptomatic medicine or end of
life or supportive care).
aplurals or other word endings
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design and key aspects of the methodological process
such as analysis and outcome measurement. The
approach is detailed in Table 2.
Outcomes of interest
We were interested in evaluating whether the interven-
tion led to a measurable impact on wellbeing for the
person with dementia and their family, including aspects
of care of relevance at the EOL. For all statements our
primary outcomes were:
 At the EOL QOL, symptoms and distress. These
could be captured using validated tools such as the
Symptom Management-End-of-Life in Dementia
[32] and the Comfort Assessment in Dying with
Dementia (CAD-EOLD) [32].
 The families’ satisfaction with care. This could be
captured by the Satisfaction With Care at the
End- Of-Life in Dementia scale [32].
 Types of care and treatment such as whether the
person was admitted to a hospice or was
hydrated artificially.
 Place of death.
For each study if reported we detailed whether the
intervention was actually implemented, such as docu-
mentation of a SFC.
Our secondary outcomes of interest were
 Measures of family wellbeing and QOL.
 Economic costs.
Data extraction and analysis
We extracted characteristics of the studies directly into
tables. These included country of origin, study design,
population characteristics, description of intervention,
type of analysis and results.
We sought, if appropriate, to combine trial results
in a meta-analysis. Extraction of the data was under-
taken by one researcher (ME/BC) and checked by an-
other (ME/BC/VV/KM). To allow the reader to
consider the effect of the intervention we sought to
present fully the findings, including the size of effect.
We sought to standardise the presentation of results.
For analysis using continuous variables to compare
outcomes between participants receiving the interven-
tion and not receiving the intervention we present, if
appropriate, the mean difference (MD) and standard
deviation (SD). For those using dichotomous data we
present, if appropriate, the odds ratio (OR) and 95 %
confidence interval (CI).
Results
The databases searched identified 5,548 citations. At
screening for eligibility, for 122 it was necessary to ascer-
tain eligibility by reading full text articles. Of these,
agreement was easily reached to exclude 104 as they did
not report an evaluation or the intervention was ineli-
gible. A further 10 studies were judged by consensus of
the wider research team as not eligible [18, 20–25,
33–35]; they are listed with reasons for exclusion in
Table 3. The remaining seven studies were eligible
[36–42]. A flowchart describing the screening processes is
shown in Fig. 1.
Table 2 Definitions used for the grades of evidence
Grade I: Randomised controlled trial (RCT)
IA Calculation of sample size and accurate, standard definition
of outcome variables
IB Accurate and standard definition of outcome variables.
IC Neither of the above
Grade II: Prospective study with a comparison group (non randomised
controlled trial, observational study) or retrospective study which
controls for confounding variables
IIA Calculation of sample sizea and accurate, standard definition
of outcome variables and adjustments for the effects of important
confounding variables
IIB One or more of the above
IIC Neither of the above
Grade III Retrospective or observational or cross-sectional studies
IIIA Comparison group, calculation of sample size and accurate,
standard definition of outcome variables
IIIB One or more of the above
IIIC Neither of the above.
aIf sample size above 1000 or more we considered this criteria to have
been reached
Table 3 List of excluded studies with reasons for exclusions
Study Reason for exclusion
Bass et al. 2003 [33] Intervention ineligible
Callahan et al. 2006 [20] Not evaluating QOL in patients
with advanced dementia
Challis et al. 2002 [23] No outcome on QOL at the EOL
Eloniemi-Sulkava et al. 2001 [24] No outcome on QOL at the EOL
Eloniemi-Sulkava et al. 2009 [25] No outcome on QOL at the EOL
Fortinsky et al. 2009 [21] No outcome on QOL at the EOL
Samus et al. 2014 [34] No outcome on QOL at the EOL
Shega et al. 2008 [18] Whilst appropriate outcomes were
compared with those that received
hospice care with those that didn’t
both groups were assessed for
palliative care needs. (QS5)
Specht et al. 2009 [35] No outcome on QOL at the EOL
Vickrey et al. 2006 [22] No outcome on QOL at the EOL
These are the studies excluded where because of lack of clarity it was
necessary to discuss their inclusion in the review at a regular research meeting
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Three included studies were from USA [37, 39, 40],
two from Belgium [41, 42], one from Canada [36] and
one from the UK [38]. None were RCTs. All reported
data collected retrospectively. They either (1) compared
one group of persons with dementia who underwent the
intervention with another group who did not [39–42] or
(2) compared data collected before and after implemen-
tation of the intervention in the same NH site [36–38].
Combining any of the studies in a meta-analysis was not
appropriate because of study design and heterogeneity
across studies. No studies were rated as the highest
grade of quality. Four were graded as IIA as they were
cohort studies with comparative groups, had large sam-
ples, controlled in their analyses for known key con-
founders such as age and had robust outcome measures
[39–42]. The other three were graded as IIIB as they
were before-and-after studies and used robust outcome
measures [36–38].
We found no studies that assessed outcomes specific-
ally relevant to EOL care that may have supported S4
which recommended a case management approach. Of
note we excluded the PEACE programme [18], which de-
scribes case management in dementia with a palliative
care focus. We excluded this as the absence of a
comparison group made interpretation of the EOL care
outcomes difficult. However, we acknowledge that bene-
fits of care co-ordination prior to the terminal phase are
reported [43].
Four of the seven eligible studies were of an intervention
on SFC as recommended for S5 [39–42] and three for S9;
which involved a palliative care assessment [36–38].
Statement 5 (S5): People with dementia, while they have
capacity, have the opportunity to discuss and make
decisions, together with their carer/s, about the use of
advance statements, advance decisions to refuse
treatment, Lasting Power of Attorney and Preferred
Priorities of Care
Four studies were relevant to S5 [39–42]. All were post-
mortem studies comparing EOL outcomes dependent on
whether or not prior to loss of mental capacity the de-
ceased person had made a documented SFC. All studies
provided descriptions of a SFC including (1) an expressed
desire to limit care [39], (2) discussions about the goals
and desired direction of care, particularly EOL care, in the
event that the individual is or becomes incompetent to
make decisions [41, 42], or (3) documentation of individ-
ual wishes with respect to life-sustaining treatment
Fig. 1 Flow chart of review process
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described as a ‘living will’ or their choice of a surrogate
decision maker, as in a durable power of attorney for
healthcare [40].
EOL care outcomes included the type of care provided,
symptoms and distress experienced, and place of death.
All studies used regression analysis to control for poten-
tial confounders. Three of the studies involved at the
EOL participants with severe dementia [39, 41, 42]. The
fourth included participants with cognitive deficits [40].
Table 3 provides details on the studies.
Two studies were undertaken by the same team but
used different samples [41, 42]. All participants were
resident in a NH. They both used cross-sectional data
on deaths from large nationally representative surveys of
NH residents. In one survey, data were collected on 764
residents within 345 NH [41], and in the other on 101
residents in 69 NH [42]. Data on care outcomes were
collected by questionnaire.
In the other two studies their samples examined par-
ticipant data from the Health and Retirement Study
(HRS), a large nationally representative longitudinal co-
hort study of people aged 60 years or over. The study
data were linked to Medicare claims spending in the last
six months of life and measures of aggressive or life-
sustaining treatment, such as feeding tube placement, in-
tensive care use, and in-hospital death. Both report data
on just under 4,000 individuals. Proxy respondents at
post-mortem interview were asked if there was a SFC.
One study details that proxy respondents were most
commonly (48 %) an adult child [39].
We graded the quality of these four studies at IIA.
Overall the studies showed mixed impact of the
intervention.
Statement about future care
The proportion of participants at EOL who had a docu-
mented SFC varied. In both studies by Vandervoort and
colleagues a SFC was reported as present for 17 % of the
participants [41, 42]. In one study, 1 % (n = 8) of partici-
pants had appointed a legal representative [42], and the
most frequent treatment directives reported were do-
not-hospitalise (DNH) (2.5 %) and do-not-resuscitate
(DNR) (2.1 %) orders.
In the evaluations using data from the HRS study, one
reports that for 44.9 % (of 3746) who had loss of cap-
acity (due to any diagnosis) a SFC was in place [39], and
in the other a SFC was in place for 36.5 % of the sample
with severe dementia [40].
Quality of life, symptoms and distress in the person
with dementia
Two of the studies explored QOL, symptoms and distress;
one used the CAD-EOLD on comfort assessment [42], the
other the Edmonton Symptom Assessment Scale or nurse
report. [41] One study found no statistical differences in
the last week of life between those who had a SFC and
those who did not in terms of symptoms (See Table 4)
[41]. In the other study regression models showed no sta-
tistically significant difference in overall scores on comfort
between those with and without a SFC [42]. However, for
three of the twelve subscale analyses there was a signifi-
cant reduction in emotional distress. This was for
 Having a SFC compared to not having a SFC (OR
2.99; CI 1.1, 8.3),
 The SFC requested DNH (OR 2.54; CI 0.8, 7.7),
 The SFC requested DNR (OR 3.45; CI 1.1, 11).
Types of care or treatment
Two studies explored if having a SFC made a difference to
whether the person with dementia received aggressive or
life-sustaining treatment [39, 40]. One explored outcomes
in two samples: those with dementia living in the commu-
nity outside of a NH and those residing in a NH [39].
They found no significant difference in the proportion re-
ceiving aggressive or life-sustaining treatment between
those who had a SFC and those who did not, but those
who lived in the community (outside of a NH) and had a
SFC were significantly less likely to be admitted to an in-
tensive care unit (10.2 % v 19.6 % p value <0.01).
The other study found, in people with loss of capacity
due to any diagnosis, that those who had a SFC were sig-
nificantly less likely to receive aggressive or life-sustaining
treatment (OR 0.33; CI 0.19, 0.56) [40]. Likewise they
found that those who had appointed a durable power of
attorney for healthcare were less likely to receive such
treatment (OR 0.54; CI 0.34, 0.86). They also explored
whether there was a greater chance that those with a SFC
compared to those who did not would receive ‘comfort
care’ (described as being comfortable and pain-free while
forgoing extensive measures to prolong life) and limited
care only (described as limited care in certain situations,
as opposed to all care possible in order to prolong life).
For both limited and comfort care analysis showed an as-
sociation with having a SFC (OR 1.79 CI 1.28, 2.50; OR CI
2.59, CI 1.06, 6.31 respectively).
Place of death and other outcomes
Three studies looked at place of death [39–41]. One
found those with a SFC compared to those without were
significantly less likely to die in a hospital; in the com-
munity sample 13.9 % versus 31.8 % and in the NH
14.6 % versus 20.6 % respectively [39]. In another study
there was no difference in regards to a SFC (OR 0.71; CI
0.47, 1.07) but there was a difference if a durable power
of attorney for healthcare had been made (OR 0.72; CI
0.55, 0.93) [40]. The third study found no difference,
however it differed its analyses, it compared whether a
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Table 4 Studies addressing issues in Statement 5: Study characteristics, intervention content and outcomes reported
Study & country Design Population Intervention content, analysisa and
number with a statement about
future care (SFC) or related document
Results: Impact on care outcomes of having or not having
advanced directives or related documentsa
Nicholas 2014
et al. [39] USA
Retrospective study which controls for
confounding variables Data from 3876
participants of the Health & Retirement
Study (HRS) who died between 1998
and 2007. Study exit interview
(after death) by knowledgeable
informant (KI)
Age 65 years and over, consented to
share Medicare claims data for last
6 months of life. Includes nursing
home (NH) (n = 1812) and community
dwelling people (n = 2064). 21.7 %
severe dementia, 43.1 % mild dementia
or cognitive impairment, 35.2 % normal
cognition (as assessed at last HRS
interview –mean 436 days before
death – using validated cognition
measures). Results only reported
for severe dementia.
Comparison of end-of-life care with
those that had and those that didn’t
have a written advance directive (AD)
or “living will” as stated by proxy
respondent in post-mortem interview.
General liner model and logistic
regression to generate predicted
spending and probabilities of use in
last six months of life. Adjustments
were made for patient characteristics,
including cognitive functioning, an
AD and their interaction, stratified by
NH use in last 6 months. 36.4 % of
people with severe dementia had a
treatment limiting AD (40 % of NH,
27.4 % of community dwelling).
REGRESSION: results presented for subgroup with
severe dementia only
Medicare spending ($1,000)
Community-dwelling NH
No SFC 32.2 24.7
SCF 20.7*** 22.5
Hospital death (%)
Community-dwelling NH
No SFC 31.8 20.6
SFC 13.9*** 14.6**
Life sustaining treatment (%)
Community-dwelling NH
No SFC 19.8 11.6
SFC 10.6 9.8
ICU use (%)
Community-dwelling NH
No SFC 19.6 10.8
SFC 10.2*** 7.1
Difference in results of AD and no AD not significant except
where **/*** P value ** < 0.05, ***p < 0.01
Silveira 2010
et al. [40] USA
Retrospective study which controlled
for confounding variables. Data from
3746 participants in HRS Study who
died between 2000 and 2006. Study
exit interview (after death) by
knowledgeable informant (KI) – a
relative most commonly as adult child
Age 60 years and over, died 2000–2006,
46 % had cognitive impairment prior to
death (but not dementia specific) as
stated by KI
Comparison of end-of-life care as
stated by KI in post-mortem interview
with those that had and those that
didn’t have a written SFC or Power
of Attorney (PoA).
REGRESSION: Adjusted odds ratio and (95 % confidence
interval) for presence versus absence of a living will or
a PoAa
SFC PoA
Multiple logistic regression. Adjustments
made for socio-demographic and clinical
characteristics. 42.5 % required
decision-making at end of life, 70 % of
whom lacked capacity, 67.6 % of whom
had SFC. 83 % who requested limited
care and 97 % who requested comfort
care received care consistent
with preferences
Hospital death 0.71 (0.47, 1.07) 0.72 (0.55, 0.93)a
All care 0.33 (0.19, 0.56)a 0.54 (0.34, 0.86)a
Limited Care 1.79 (1.28, 2.50)a 1.18 (0.75, 1.85)
Comfort Care 2.59 (1.06, 6.31)a 2.01 (0.89, 4.52)
All care is care under any circumstances to prolong life,
Limited care is care in certain circumstances, this is as
opposed to all care possible in order to prolong life,
Comfort care is comfortable and pain-free while forgoing
extensive measures to prolong life.
aDifference statistically significant
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Table 4 Studies addressing issues in Statement 5: Study characteristics, intervention content and outcomes reported (Continued)
Vandervoort 2012
et al. [41] Belgium
Retrospective study which
controls for confounding
variables
NH resident. Presence of a written doctors orders
to withhold treatment, such as do-
not-hospitalise or do-not-resuscitate,
or advance patient directive (SFC),
such as a “living will” as stated by
nurse in post-mortem questionnaire.
This questionnaire also captured care
outcomes, Comparison of outcomes
dependent on presence of SFC.
Multivariate logistic regression model.
Outcomes only on SFC presented.
(The others are not relevant to
this review).
REGRESSION: Adjusted odds ratio and 95 % confidence
interval presented on SFC and patient directives only
Study of deaths in NH of
residents with dementia. All
NH (594) invited to participate.
Post death questionnaire
completed by nurse.
Diagnosis of dementia, and
severity, as stated by nurse.
Symptoms in the last week of life using Edmonton
Symptom Assessment Scale
Died in 2-month study period in
2006. 72 % female, 78 % 80 years
and above. 63 % severe and 37 %
moderate dementia. 764 deaths in
345 NH (58 % response rate).
Pain 0.72 (0.37, 1.40)
Tiredness 1.08 (0.54,2.15)
Nausea 0.55 (0.20,1.51)
Depression 1.42 (0.73,2.77)
Anxiety 1.38 (0.73,2.58)
Drowsiness 0.78 (0.40,1.51)
Appetite 1.14 (0.55,2.40)
Shortness of breath 1.19 (0.63, 2.23)
QOL last week of life 1.14 (0.58,2.24)
Mildness of death 1.70 (0.70, 4.12)
Death in hospital or
palliative care unit
2.09 (0.92, 4.72)
All odds ratios not significant
Vandervoort 2014
et al. [42] Belgium
Retrospective study which controls
for confounding variables. Study
of NH of residents with dementia
who died within a 3-month period
in 2010 (representative sample
using random cluster-sampling).
Post death questionnaire completed
by nurse, GP, family member or
friend & NH administrator.
Diagnosis of dementia as stated by
nurse or GP. 58 % female, 84 %
80 years and above. 51 % very
severe dementia, 25 % severe
dementia, 24 % moderate or
mild dementia
Comparison of scores on the
Comfort Assessment in Dying
in Dementia Scale (CAD-EOLD).
REGRESSION: Mean (standard deviation) score in total and
subscales of the CAD-EOLDa
Relative available to complete
questionnaire. 101 deaths in
69 NH (58 % response rate).
Multivariate logistic regression
adjusting for age, gender, level
of dementia and sentinel events.
SFC No SFC
17.5 % had a written advanced
directive, 56.7 % had GP orders
Total 31.9 (7.1) 29.1 (6.3)
Physical distress 8.8 (2.9) 8.2 (2.2)
Dying symptoms 8.6 (2.4) 8.0 (2.6)
Emotional distress 10.2 (2.3)** 9.0 (2.3)
Wellbeing 6.2 (1.9) 5.9 (1.9)
DNH No DNH
Total 32.8 (6.4) 29.1 (6.4)
Physical distress 8.8 (2.9) 8.2 (2.2)
Dying symptoms 9.1 (2.2) 8.0 (2.6)
Emotional distress 10.4 (1.8)*** 9.0 (2.4)
Wellbeing 6.4 (2.0) 5.9 (1.9)
DNR No DNR
Total 32.9 (5.6) 29.1 (6.5)
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Table 4 Studies addressing issues in Statement 5: Study characteristics, intervention content and outcomes reported (Continued)
Physical distress 9.3 (2.7) 8.1 (2.7)
Dying symptoms 8.6 (2.3) 8.1 (2.7)
Emotional distress 10.6 (1.7)**** 9.0 (2.4)
Wellbeing 6.5 (1.6) 5.9 (1.9)
PDMA No PDMA
Total 29.1 (7.6) 29.4 (6.3)
Physical symptoms 8.2 (2.6) 8.1 (2.3)
Dying symptoms 7.8 (3.0) 8.0 (2.6)
Emotional distress 9.4 (3.3) 9.1 (2.3)
Wellbeing 5.6 (0.9) 5.9 (1.9)
aAll adjusted odds ratios reported as not significant apart
from: ** 2.99 (CI 1.1, 8.3) ***2.54 (0.8, 7,7), ****3.45 (CI 1.1,11).
aAll trials presented the outcomes reported here as a primary outcome. Results presented are the most complete reported in the published paper. CAD-EOLD = Comfort Assessment in Dying in Dementia Scale,
DNH = do-not-hospitalise, DNR = do not resuscitate, KI = knowledgeable informant, GP = general practitioner/primary care physician, HRS = Health & Retirement Study, NH = nursing home, PDMA = proxy decision
maker assigned, PoA = Power of Attorney. QOL = quality of life, SFC = statement about future care
C
andy
et
al.BM
C
Palliative
Care
 (2015) 14:51 
Page
9
of
15
person died in hospital or a palliative care unit with
whether or not they died in a NH [41]. One study re-
ported economic costs and found the presence of a SFC
reduced Medicare spending in community dwelling per-
sons [39]. No studies reported family outcomes, adverse
effects or economic costs.
Statement 9 (S9): People in the later stages of dementia
are assessed by primary care teams to identify and plan
their palliative care needs
Table 5 provides details on study characteristics and
their results.
Three studies were relevant to S9 [36–38]. They all in-
volved residents of NH who had died with dementia and
in each the focus of the intervention involved assess-
ment and planning of palliative needs. All were before-
and-after studies where the unit of analysis was the NH.
One study was from the USA [37], one from Canada
[36], and one the UK [38].
All were staff educational intervention programs de-
signed to facilitate recognition of the needs of residents
with dementia who were approaching the EOL. Topics
included symptom assessment and care. The largest
study included 458 residents within nine NH; seven
homes took part in the intervention and two acted as
controls to gauge temporal trends in care [37]. The
other two studies involved one NH [36, 38]. In one study
all participants had at EOL advanced dementia [36], in
another the majority did [38] and in the other the major-
ity had cognitive deficits [37].
The studies were graded at IIIB. Overall the evidence on
the impact of the palliative care intervention was mixed.
Person with dementia quality of life, symptoms
and distress
One study reported on symptoms of pain or distress at
the EOL [36], it found no significant mean change in
pain symptom scores or dying with dignity.
Types of care and treatment
One study found a significant increase in hospice referral
(before 4 % of residents were referred whereas following
the intervention 6 % were referred, p value > 0.05) [37].
There were also reported statistically significant changes
evident in four of the five other outcomes reported on
aspects of care:
 Assessed for pain (pre intervention 18 %, and
post 60 %),
 Received non-pharmacological treatment (pre 15 %,
post 34 %),
 Had a DNR order (pre 58 %, post 65 %),
 Had a DNR indicator or ‘flag’ in a chart outside of
their notes (pre 45 %, post 60 %).
There was no significant difference in the number
receiving pain medication.
Satisfaction with care at the end of life
Two studies reported satisfaction with care at the EOL
[36, 38]. They both used the validated After Death
Bereaved Family Member Interview Toolkit, neither re-
ported significant change in family satisfaction with care.
Place of death and other outcomes.
One study reported the place of death; it found a signifi-
cant increase in deaths occurring within the NH as op-
posed to hospital, from 47 % (14/30) pre-intervention to
76 % (22/29) post (p value 0.02) [38]. In addition, those
whose wishes had been recorded were more likely to die
in their preferred place of care.
No studies reported on family outcomes, adverse events
or economic costs.
Discussion
We sought to identify and examine the quality and
quantity of evidence underpinning the UK quality state-
ments designed to help drive improvements in care for
the growing number of people dying with dementia. We
located evidence to inform the three statements of the
NICE Quality Standards (QS1) that are most pertinent
to EOL care of people with moderate to severe dementia
(S4, S5, S9). We found no studies that met our inclusion
criteria that related specifically to S4, which recom-
mends a case management approach. Whilst for this
statement we identified nine studies that matched our
criteria on interventions (see Table 3), we were not able
to include them in this review due to the nature of their
study design and outcome data. In particular, a lack of a
comparison group made interpretation of the EOL care
outcomes difficult. Other excluded studies were trials of
case management but they did not assess the benefit for
participants with advanced dementia at the EOL. The
case management approach highlights aspects of care
that we would assume are relevant to a person irrespect-
ive of the stage of their disease, in particular a named
care coordinator responsible for assessment and an on-
going personalised care plan. Whilst it may be reason-
able to expect that a case management approach
initiated earlier in the illness might be continued and
have benefits right up until the time of death, stronger
evidence for the effectiveness of case management at this
particular time would be helpful.
For the other statements the evidence was limited by
the number and heterogeneity of the included studies.
We identified four studies relevant to S5, which recom-
mends that early in dementia discussion is undertaken
about making a statement about future care (SFC). Two
of these studies explored the impact of making advanced
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Table 5 Studies addressing issues discuss in Statement 9: Study characteristics, intervention content and outcomes reported
Study and
country
Design Population Intervention content, data collection, analysis
and number with palliative care assessment
Resultsa: Impact on care outcomes of assessment in
the community to identify, and plan palliative care
needs
Arcand et al.
2009 [36] Canada
Pre and post intervention study. Relatives of residents who died with
advanced dementia, and where
dementia was the main physician
recorded diagnosis. pre intervention
Mean age 91 years and 90 % female
and post intervention. 87 years and
71 % female.
Intervention educational Delivered by
geriatric nurse specialist for all care home
staff and physicians. Topics included
symptom control & palliative care in
advanced dementia, advance care
planning & medical guidelines for
considering prognosis. Information
booklet for use by staff and to give
to family members.
Mean difference in scores and confidence
intervals pre and post interventiona
One 387 bed nursing home (NH). 48 deceased residents, 27
pre-intervention, and 21
post-intervention.
Data collection 4–16 months post
bereavement. Family satisfaction with
care using validated scale “After death
bereaved family member interview/
NH version”.
Communication 1.40 [−3.04, 0.24]
Unit of analysis NH Analysis t-tests statistics
Care according to
Patient’s wishes −0.10 [−1.18, 0.98]
Symptom control −0.80 [−1.96, 0.36]
Dying with dignity 0.10 [−1.22, 1.42]
Family emotional
Support 1.00 [−2.85, 0.85]
Satisfaction −1.00 [−2.05, 0.05]
ausing “After death bereaved family
member interview/ Nursing Home version”.
None of the mean differences were signficiant.
Hanson et al.
2005 [37] US
Pre and post intervention study, 7 NH
with another 2 NH acting as a control.
This was to gauge temporal trends.
All residents, 43 % had dementia
diagnosis and 76 % cognitive
impairment.
Intervention educational Plan-do-study-act
design. NH identified staff members to
form interdisciplinary palliative care team
who attended one day conference;
education on hospice enrolment and
services, pain management, advance care
plans and communication. Then monthly
in house education and support (x6
sessions) available to all clinical staff;
help with designing procedures &
protocols and the use of assessment tools.
Results in numbers:
Pre (%) Post
(%)
N = 345 n = 346
Unit of analysis NH Mean age 82 years, 74 % white,
81 % female.
Data collection from medical records
and after death interview at least
three months after the death.
Hospice care 4.0 6.8*
345 residents pre intervention
and 346 post intervention
Analysis chi-squared statistics
Pain assessed 18 60*
113 residents in 2 control NHs No
significant differences between
intervention and control NHs
at baseline
Receiving pain
Medication 77 81
Receiving non-drug
Treatment for pain 15 34*
DNR order 58 65*
DNR flagged in chart 45 60*
Documented discussion
on preferences
4 17*
*Statistically significant, P value equal
or less than 0.05, chi-squared test
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Table 5 Studies addressing issues discuss in Statement 9: Study characteristics, intervention content and outcomes reported (Continued)
Livingston, 2013
et al. [38] UK
Pre and post intervention study, Residents with dementia of any
severity (most advanced dementia
MMSE mean = 5)
Educational interventional 10 session
training program for all staff covering
structured listening, empathy
communication skills, advance care
planning and preferred place of care.
Pre Post X2 P value
One 120 bed NH. Residents with dementia of any
severity (most advanced
dementia MMSE mean = 5)
Data collection from medical records
& after-death bereaved family
member interview
EOL talk 04/30 13/28 15.2 0.001
Unit of an analysis the NH 59 deaths, 30 1 year pre-study,
29 1 year post study.
Analysis before and after intervention
using t-tests and Mann Whitney for
means or medians according to
data distribution
DNR orders 04/28 16/22 17.4 0.001
EOL talk +
DNR order 01/04 12/16 5.3 0.06
Deaths in care
home
14/30 22/29 5.3 0.02
Intervention
In line with wishes 05/07 13/13 4.1 0.04
Days in hospital
Last 3 months 4 1.25 29.0a 0.22
Care
satisfaction 7.5 (1.3) 9.1 (2.4) 17.6a 0.06
at test or Mann–Whitney
aResults presented as the most complete reported in the published paper, EOL = end of life, DNR = Do not resuscitate, NH = nursing home, X2 = Chi –Squared test
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decisions on QOL, symptoms and distress at the EOL.
In both no significant differences in these domains were
found between those who had made a SFC and those
who had not [41, 42]. However, in one study a weaker
(subgroup) analysis showed evidence to suggest that the
presence of a SFC may reduce emotional distress in the
person with dementia [42]. There was mixed evidence
on the effect of a SFC on types of treatment at the EOL
[39, 40], for instance in one study there was a signifi-
cantly lower chance of receiving aggressive or life sus-
taining treatment if the person had a SFC [40], but this
was not found in the other study [39]. We also found
mixed results on whether the person died in hospital,
with one study finding an association between not hav-
ing a SFC and dying in a hospital [39], and another study
reported no significant difference [41]. The differences
in findings between the studies could be due to hetero-
geneity such as measuring impact using different scales
or because of different characteristics in the populations
or settings.
Three studies were relevant to S9 which recommends
palliative care assessment [36–38]. Outcomes reported
across these studies varied and so it is difficult to draw
conclusions. For example, following the intervention in
one study there was no significant improvement in
symptom control [35], in another study there was sig-
nificantly more assessment of pain but no increase in
the number of participants receiving pain medication
[36]. In one study, post intervention significantly more
people with dementia received hospice care [37] and in
another more received care at the EOL in line with their
wishes [38]. The differences in findings between the
studies could be due to heterogeneity such as how the
outcome is measured, in the population considered and
differences or local limitations in delivery of the inter-
vention. Moreover our findings suggest for all state-
ments there is a need for further research to clarify the
impact of what is recommended. Our results do not sug-
gest that these quality statements should be withdrawn.
Strengths and limitations
This review was challenged by the quality of the evi-
dence identified. Although most of the included studies
involved large samples there were limitations with study
design. All used retrospective data and relied on others
for precise record-keeping and for accurate recall of
events. Three were before-and-after studies, with limited
use of an external comparison group. Therefore it is
difficult to establish cause and effect. Changes re-
ported may have occurred even if the interventions
had not been implemented. For example, NH staff
may, because of increased recognition in the public
domain of palliative care, have started to assess the
EOL needs of residents.
None of the studies were specifically designed to ex-
plore the benefits of interventions recommended in the
UK quality statements. Moreover, we had difficulties in
clearly defining our population of interest at the EOL.
People with dementia may die from dementia when it is
advanced when they are likely to have lost mental cap-
acity, or they may die with dementia as a co-morbid
condition when it is mild. Palliative and EOL needs as
understood by the quality standards are relevant in both
scenarios. However for the reason of increased relevance
we considered only evidence from studies of those facing
the EOL either with moderate to severe dementia or who
had documented loss of mental capacity.
Our review was limited by the numbers of eligible
studies and research design. In addition, we focused only
on UK statements. However, although there are guide-
lines on dementia in other countries that are specific to
EOL, we are unaware of quality statements elsewhere
that aim to drive forward aspects of practice across dif-
ferent healthcare settings. The evidence is also limited in
its application; three of the studies were conducted in
the USA where healthcare provision differs from that
available in other countries including the UK. Only
one study was undertaken in the UK. It is also diffi-
cult to comment on the overall applicability of the
findings as there was limited evidence of consistency.
Few measurements overlapped in studies and there
was considerable variation in the reported effective-
ness of the interventions. This variation may be ex-
plained by contextual differences, but it should be
remembered that the design of these studies is weak,
increasing the risk of bias in their results.
We searched widely using large citation databases and
developed our search terms, refining iteratively with test
searches and consultation within the research team that
comprised of experts in palliative care, dementia and
primary care. We used a number of terms for each state-
ment (S4, 5, 9) that illustrated its main aims. Whilst we
think that we were inclusive and broad in our approach,
the terminology within each statement lacked specificity
and may have been subject to our interpretation; a dif-
ferent group of researchers may have captured different
studies. However, the evidence available was so scarce
that we think it is unlikely that we have overlooked any
major research in this field.
To our knowledge no other published systematic re-
view has been undertaken to evaluate the evidence rele-
vant to the NICE QS1 on EOL care. There is a recent
Cochrane review on case management for people with de-
mentia in one care setting, the person’s home [44]. It
found evidence to support the benefit of this intervention.
Our review differed in that it only critiqued studies involv-
ing an intervention at EOL. At this stage many people
with dementia are residing in a care home. Moreover, our
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focus involved a QS recommending three aspects of care
that may be described in case management programs; (i)
an assessment and an ongoing personalised care plan
agreed across health and social care (ii) that identifies a
named care coordinator and (iii) addresses their individual
needs. Not all case management approaches may include
all three.
Other related research includes a systematic review of
advance care planning in general populations which it also
revealed a lack of high quality studies [17]. It may not be
surprising that the evidence is limited. We acknowledge
the potential difficulties in undertaking research in popu-
lations at the EOL and also in people with dementia, in
particular issues of capacity and consent of participants,
obtaining agreement from personal or professional con-
sultees and the ethics of randomising to a control group.
In addition there may be difficulties in engaging care staff
because of high staff turnover in NH and the perception
that research will take-up too much of staff time.
The limitations in the research evidence relevant to
other high profile healthcare clinical guidelines and ini-
tiatives are recognised, including those of the World
Health Organization [45]. Moreover, where there is a
need to provide guidance despite limited evidence, it is
rational to draw upon evidence derived from elsewhere,
such as extrapolation of findings from other populations,
from expert clinical opinion and from patient and public
consultation [46].
Conclusions
Clinical and methodological implications
Despite the weaknesses found in the literature, we do
not suggest that clinicians and commissioners should no
longer consult quality standards. These standards are
useful to advance practice. Instead we suggest that, with-
out robust supporting evidence, it is important to bear
in mind that what is recommended may have the poten-
tial for harmful effects or, more plausibly, there is a risk
that precious funds and resources are not being used to
best effect [47].
As the numbers dying with dementia increases world-
wide more high quality evidence to inform approaches to
EOL care is needed. Detection of real intervention effects
requires adequate control of any bias that may distort the
effect so as to ensure that there is no false assumption of
effectiveness and lack of possible harm. [48] We suggest
that rigorous prospective evaluation of current and new
approaches is possible and desirable with use of consent
and assent procedures guided by the Mental Capacity Act
2005. Key issues include the use of appropriate compara-
tor groups either in controlled observational studies or in
RCT perhaps using cluster designs and multi-level ap-
proaches to data analysis. Where trials cannot be con-
ducted, data from matched sites collected prospectively
can be analysed using difference-in-difference methods
that take account of policy changes over time [49]. Ap-
proaches to measuring quality of care for those with sig-
nificant cognitive impairment should be informed by
careful selection of outcome measures that can be accur-
ately rated either through use of proxies or by direct ob-
servation. Assessment of QOL in those with impaired
capacity is an area that requires further investigation [50].
Such measures can be supported by process data, selected
and collected with similar care. Whilst international evi-
dence is of value, it is important to take account of the
context of the local healthcare systems when planning in-
novations and to gain societal views by undertaking pa-
tient and public consultation. Likewise whilst we have
looked at the evidence that could be used to under-
pin the NICE QS in regards to dementia EOL care, if
QS continue to be given high priority by the UK gov-
ernment there is a case for independent evaluation of
their use and impact [12].
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